Is IL-6 a key cytokine target for therapy in COVID-19?

Jones, Simon A. ORCID: https://orcid.org/0000-0001-7297-9711 and Hunter, Christopher A. 2021. Is IL-6 a key cytokine target for therapy in COVID-19? Nature Reviews Immunology 21 (6) , 337–339. 10.1038/s41577-021-00553-8

Preview

PDF - Accepted Post-Print Version Download (349kB) | Preview

Abstract

The identification of elevated IL-6 levels in patients with severe COVID-19 led to the rapid development of clinical trials targeting this cytokine. Overall, these trials do not support the widespread use of IL-6 antagonists in hospitalized patients with mild-to-moderate disease, but IL-6 antagonists may be beneficial when rapidly deployed in patients with severe COVID-19, as we discuss here.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Publisher:	Nature Research
ISSN:	1474-1733
Date of First Compliant Deposit:	7 October 2021
Date of Acceptance:	4 April 2021
Last Modified:	16 Nov 2024 05:15
URI:	https://orca.cardiff.ac.uk/id/eprint/144740

Citation Data

Cited 56 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item